Two stocks in Healthcare
Convatec Group vs Oxford Biomedica: profit, growth, debt and price compared
Convatec Group is stronger on 5 of 6 figures: profit margin, debt, price for its expected profit, analysts' view and price trend. Oxford Biomedica is stronger on 1: sales growth.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Convatec GroupCTEC.L | Oxford BiomedicaOXB.L | |
|---|---|---|
| Net margin | Stronger: 5.0% | −23.2% |
| Revenue growth, past year | +4.40% | Stronger: +9.00% |
| Debt to equity | Stronger: 121.8% | 273.1% |
| Forward P/E | Stronger: 15.7× | Loss |
| Dividend yield | 2.25% | — |
| Analysts | Stronger: Strong buy · 19 | Buy · 8 |
| From its 200-day average | Stronger: +17.9% | −5.2% |
Share price over the past year
- Convatec Group+15.1%
- Oxford Biomedica−13.2%
20 Nov 202518 Nov 2026
Convatec Group or Oxford Biomedica: which is stronger?
- CTEC.L
Which is more profitable?
Convatec Group keeps more of each sale as profit: 5.0% against −23.2%.
- OXB.L
Which is growing its sales faster?
Oxford Biomedica is growing its sales faster: +9.00% over the past year, against +4.40%.
- CTEC.L
Which has borrowed less?
Convatec Group has borrowed less: its debt is 121.8% of what its shareholders own, against 273.1% for Oxford Biomedica.
- CTEC.L
Which costs less for the profit it is expected to make?
Convatec Group is expected to make a profit over the next year, where Oxford Biomedica is expected to make a loss.
Which pays more in dividends?
Convatec Group pays 2.25% a year in dividends for what a share costs, where Oxford Biomedica pays none.
- CTEC.L
Which do analysts rate higher?
Analysts are warmer on Convatec Group: Strong buy, against Buy for Oxford Biomedica.
- CTEC.L
Which is in the stronger price trend?
Convatec Group's price is in the stronger trend: 17.9% above its 200-day average, against 5.2% below.
What each company does
CTEC.LConvatec Group
Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally.
Reports results on 23 February 2027
OXB.LOxford Biomedica
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
Reports results on 25 March 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.